Bijoy Sagar - Stryker Chief Digital Technology Officer, Vice President
SYK Stock | USD 357.44 1.27 0.35% |
President
Mr. Bijoy S.N. Sagar is Chief Digital Technology Officer, Vice President of the Company. He is responsible for the development and execution of our digital strategy as well as our global information technology strategy. His function helps build digital services for our customers and solutions that enable excellent customer experience. He joined Stryker as Vice President, Chief Information Officer in May 2014. Prior to joining us, Mr. Sagar spent 20 years in the medical technology industry, most recently serving as Chief Information Officer for Merck Millipore, and before that as Global Head of Information Systems and a member of the Divisional Board for the 15 billion Chemicals division of Merck KGaA. Prior to joining Merck in 2006, Bijoy held various roles of increasing responsibility with Millennium Pharmaceuticals, Amgen and Eli Lilly Company. since 2018.
Age | 49 |
Tenure | 6 years |
Address | 1941 Stryker Way, Portage, MI, United States, 49002 |
Phone | 269 385 2600 |
Web | https://www.stryker.com |
Stryker Management Efficiency
The company has Return on Asset of 0.0687 % which means that on every $100 spent on assets, it made $0.0687 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1798 %, implying that it generated $0.1798 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to rise to 0.21 this year. Return On Assets is expected to rise to 0.11 this year. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B.Similar Executives
Showing other executives | PRESIDENT Age | ||
Edwin Detrick | Cigna Corp | N/A | |
Charles Lynch | Mednax Inc | N/A | |
Lance Berberian | Laboratory | 61 | |
Herbert Fritch | Cigna Corp | 64 | |
Peter Wilkinson | Laboratory | 52 | |
David Guilmette | Cigna Corp | 51 | |
Everett Neville | Cigna Corp | 59 | |
Lisa Uthgenannt | Laboratory | 57 | |
Samuel Eberts | Laboratory | 57 | |
Brian Caveney | Laboratory | 47 | |
Dominic Andreano | Mednax Inc | 52 | |
Lisa Bacus | Cigna Corp | 53 | |
Sandra Vaart | Laboratory | 64 | |
Matthew Manders | Cigna Corp | 58 | |
Jason Sadler | Cigna Corp | 55 | |
ALAN MUNEY | Cigna Corp | 63 | |
Noelle Eder | Cigna Corp | 54 | |
Mark Boxer | Cigna Corp | 59 | |
Nicole Jones | Cigna Corp | 53 | |
Kristen Lauria | Cigna Corp | 51 | |
C Richards | Mednax Inc | 50 |
Management Performance
Return On Equity | 0.18 | ||||
Return On Asset | 0.0687 |
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Silvernail, Independent Director | ||
Fink, Vice President Global Human Resources | ||
Sherilyn McCoy, Independent Director | ||
Lisa Tatum, Independent Director | ||
Robert Cohen, CTO Replacement | ||
Ronda Stryker, Independent Director | ||
Preston Wells, Vice President - Investor Relations | ||
Curtis Hall, Chief Legal Officer | ||
Ramesh Subrahmanian, Advisor | ||
Spencer Stiles, Group President Orthopaedics and Spine | ||
Andrew Pierce, Group Neurotechnology | ||
William Berry, Principal Accounting Officer, Vice President, Corporate Controller | ||
Allan Golston, Lead Independent Director | ||
Katherine Owen, Vice President - Strategy and Investor Relations | ||
Graham Mclean, President Asia-Pacific | ||
Louise Francesconi, Independent Director | ||
Kevin Lobo, Chairman of the Board, President, Chief Executive Officer | ||
Giovanni Caforio, Independent Director | ||
Jason Beach, Vice Relations | ||
Roch Doliveux, Independent Director | ||
David Floyd, Group President of Orthopaedics | ||
William Jellison, CFO and VP | ||
Yin Becker, Vice President - Communications, Public Affairs and Corporate Marketing | ||
M Fink, Chief Human Resource Officer, Vice President | ||
Timothy Scannell, Group President of Medsurg and Neurotechnology | ||
William Parfet, Non-Executive Independent Chairman of the Board | ||
Robert Fletcher, Vice President Chief Legal Officer | ||
Dean Bergy, VP and Corporate Secretary | ||
Rajeev Suri, Independent Director | ||
Alan Douville, Chief VP | ||
Glenn Boehnlein, Chief Financial Officer, Vice President | ||
J Pierce, Group President MedSurg and Neurotechnology | ||
Viju Menon, Group President - Global Quality and Business Operations | ||
Lonny Carpenter, Group President - Global Quality and Operations | ||
Bijoy Sagar, Chief Digital Technology Officer, Vice President | ||
Mary Brainerd, Independent Director | ||
Srikant Datar, Independent Director | ||
Michael Hutchinson, General Counsel | ||
Bronwen Taylor, Vice President - Compliance and Risk Management | ||
Howard Cox, Independent Director | ||
Steven Benscoter, Vice President - Human Resources | ||
Kathryn Fink, Chief Human Resource Officer, Vice President | ||
Scott Bruder, Vice President Chief Medical and Scientific Officer |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.18 | ||||
Return On Asset | 0.0687 | ||||
Profit Margin | 0.15 % | ||||
Operating Margin | 0.24 % | ||||
Current Valuation | 143.18 B | ||||
Shares Outstanding | 380.26 M | ||||
Shares Owned By Insiders | 6.48 % | ||||
Shares Owned By Institutions | 78.79 % | ||||
Number Of Shares Shorted | 3.75 M | ||||
Price To Earning | 63.07 X |
Currently Active Assets on Macroaxis
When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Stryker Stock please use our How to buy in Stryker Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Stryker Stock analysis
When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Stocks Directory Find actively traded stocks across global markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Stryker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stryker. If investors know Stryker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stryker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.027 | Dividend Share 3.05 | Earnings Share 8.23 | Revenue Per Share 53.999 | Quarterly Revenue Growth 0.118 |
The market value of Stryker is measured differently than its book value, which is the value of Stryker that is recorded on the company's balance sheet. Investors also form their own opinion of Stryker's value that differs from its market value or its book value, called intrinsic value, which is Stryker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stryker's market value can be influenced by many factors that don't directly affect Stryker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.